首页 > Autophagy > MEK
MEK
T6692 TAK-733 MEK Inhibitor TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
T6324 BIX 02188 BIX02188 is a specific MEK5 inhibitor (IC50: 4.3 nM), also inhibits ERK5 catalytic activity (IC50: 810 nM), and does not inhibit closely related kinases MEK1/2, JNK2, and ERK2.
T2416 BIX02189 BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM.
T6843 GDC-0623 GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
T6223 U0126-EtOH U0126-EtOH, a non-ATP competitive specific inhibitor of MEK1/2, with the IC50 for MEK1/2 is 0.07 μM/0.06 μM. The affinity of U0126-EtOH for ΔN3-S218E/S222D MEK is100-fold higher over PD98059.
T6785 BI-847325 BI-847325 is a selective dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.
T6057 URMC-099 URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
T6131 Pimasertib (AS-703026) Pimasertib is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
T2623 PD98059 PD98059 is a non-ATP competitive MEK inhibitor (IC50: 2 μM) in a cell-free assay; no direct inhibition of ERK1/2.
T2443 CI-1040 PD184352 (CI-1040, an ATP non-competitive MEK1/2 inhibitor (IC50=17 nM), has been used in trials studying the treatment of lung cancer, breast cancer, breast neoplasms, pancreatic cancer, and colorectal cancer.
T2327 Pelitinib Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
T2708 SL327 SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier.
T6077 ZM 447439 ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
T3001 Honokiol Honokiol is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
T6152 PD318088 PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.
T6189 PD0325901 PD0325901(IC50=0.33 nM) is a specific and non-ATP-competitive MEK inhibitor, probably 500-fold more efficiency activity than CI-1040 on phosphorylation of ERK1 and ERK2.
T6419 BMS-536924 BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
T6218 Selumetinib (AZD6244) Selumetinib (AZD6244), an effective, greatly specific MEK1 and ERK1/2 phosphorylation inhibitor, is with IC50 of 14 nM and 10 nM, respectively.
T2508 Binimetinib (MEK162, ARRY-162, ARRY-438162) Binimetinib (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay.
T2610 BMS-599626 BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
T6083 AZD8330 AZD8330 is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.
T6039 TAK-285 TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
T2125 Trametinib (GSK1120212) Trametinib is a dual-kinase inhibitor that is used in the treatment of advanced malignant melanoma. Trametinib therapy is associated with transient elevations in serum aminotransferase and alkaline phosphatase levels during therapy, but has yet to be linked cases of clinically apparent acute liver i
T6636 Refametinib (RDEA119, Bay 86-9766) Refametinib (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).
T3623 Cobimetinib Cobimetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) (IC50: 0.9 nM). Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tu
T6066 SCH772984 SCH772984 is a new-type, selective inhibitor of ERK1(IC50=4 nM),ERK2(IC50=1 nM).
T6971 RO5126766 (CH5126766) RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM,19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1.
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科研,我们不为任何其他用途提供产品和服务